Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Christelle de la Fouchardière

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2291-5693; OpenAlex author ID A5060536774. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 1, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers, 1 trial · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 27

  1. Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op-25-00358↗
  2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  3. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  4. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  5. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  6. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  7. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  8. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  9. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  10. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  11. Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. Last author DOI 10.3390/cancers14215413↗
  12. A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3. Co-author DOI 10.3390/jpm12040623↗
  13. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinica… First author DOI 10.1016/j.esmoop.2021.100318↗
  14. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  15. Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. Co-author DOI 10.3390/cancers13143515↗
  16. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  17. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  18. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  19. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  20. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317570↗
  21. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Last author DOI 10.1634/theoncologist.2018-0786↗
  22. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study. Last author DOI 10.3747/co.26.4903↗
  23. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Last author DOI 10.3892/ol.2017.6061↗
  24. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Co-author DOI 10.18632/oncotarget.8527↗
  25. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗
  26. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
  27. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗

Trials 1

  1. Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT03943667↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 9 shared papers, 2011–2026 · strength 0.79
  2. Eric Van Cutsem · 4 shared papers, 2020–2025 · strength 0.62
  3. Teresa Mercade Macarulla · 4 shared papers, 2020–2025 · strength 0.62
  4. Zev A. Wainberg · 3 shared papers, 2023–2025 · strength 0.54
  5. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  6. Eileen Mary O'Reilly · 3 shared papers, 2023–2025 · strength 0.54
  7. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  8. Andrew Scott Paulson · 3 shared papers, 2023–2025 · strength 0.54
  9. Roberto Pazo-Cid · 3 shared papers, 2023–2025 · strength 0.54
  10. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
  11. Davide Melisi · 3 shared papers, 2023–2025 · strength 0.54
  12. Tanios Bekaii‐Saab · 3 shared papers, 2023–2025 · strength 0.54
  13. Richard A Hubner · 3 shared papers, 2023–2025 · strength 0.54
  14. Shubham Pant · 3 shared papers, 2023–2025 · strength 0.54
  15. Matthieu Sarabi · 5 shared papers, 2017–2022 · strength 0.51
  16. Pascal R. Hammel · 5 shared papers, 2015–2026 · strength 0.51
  17. Nicolas Williet · 4 shared papers, 2021–2024 · strength 0.47
  18. Jerome F. Cros · 4 shared papers, 2016–2026 · strength 0.44
  19. Romain Coriat · 4 shared papers, 2015–2026 · strength 0.40
  20. Christophe Tournigand · 3 shared papers, 2020–2026 · strength 0.39
  21. Thierry André · 3 shared papers, 2020–2026 · strength 0.39
  22. Christophe Louvet · 3 shared papers, 2020–2026 · strength 0.39
  23. Fabienne Portales · 4 shared papers, 2020–2021 · strength 0.38
  24. Yves Rinaldi · 2 shared papers, 2024–2026 · strength 0.37
  25. Cindy Neuzillet · 2 shared papers, 2024–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.